

Chromosomal Characteristics of Human Preimplantation Embryos Assess by Comparative Genomic Hybridization

Matchuporn Sukprasert ¹, Matchuporn Sukprasert ² and Choktanasiri W³

¹ Mahidol university

Received: 13 December 2014 Accepted: 3 January 2015 Published: 15 January 2015

Abstract

In recent years, more women are getting married and starting a family at an older age. Advanced maternal age (AMA) is defined as age 35 years or more for the mother. This group has been observed to have a high risk of chromosomal abnormalities in their embryos during pregnancy because the quality of oocytes correlate with maternal age and corresponding reproductive clinical outcomes (1). In 2013, Harton et al. reported that higher maternal age appears to be associated with increased risk of aneuploidy in embryos :<35 yrs (53.1

Index terms—

1 I. Introduction

n recent years, more women are getting married and starting a family at an older age. Advanced maternal age (AMA) is defined as age 35 years or more for the mother. This group has been observed to have a high risk of chromosomal abnormalities in their embryos during pregnancy because the quality of oocytes correlate with maternal age and corresponding reproductive clinical outcomes (1). In 2013, Harton et al. reported that higher maternal age appears to be associated with increased risk of aneuploidy in embryos :<35 yrs (53.1%), 35-37 yrs (68.2%), 38-40 yrs (73.7%), 41-42 yrs (85.8%), >42 yrs (92.6%) from 451 blastomeres and <35 yrs (31.7%), 35-37 yrs (44.2%), 38-40 yrs (43.1%), 41-42 yrs (76.3%), >42 yrs (84.8%) from 462 blastocysts (2). Moreover, Menken et al. reported on the effects of maternal age on fertility with a decrease in birth rates when maternal age is >= 35 yrs(3). For this reason, assisted reproductive technology (ART) and preimplantation genetic screening (PGS) can be help to infertile couples and patients at high risk of there being chromosome abnormalities in the embryo. PGS is the technology used for screening chromosome abnormalities to selectively transfer euploid embryos in IVF. Patients using PGS have a higher implantation rate and pregnancy rate compared to those using morphological assessment of embryos alone (4-10). However, Schoolcraft et al. and Forman et al. reported that PGS improved implantation rates but did not improve pregnancy rates (8, 9).

The European Society of Human Reproduction and Embryology (ESHRE) Preimplantation Genetic Diagnosis (PGD) consortium data collection XII showed cumulative data from 1999 to 2010 and found that the greatest indication of infertility in couples using PGS was AMA (32%) and the most commonly used method of biopsy was cleavage stage (blastomere) aspiration (82%) (11). The advantage of blastomere biopsy was that chromosome abnormality screening can be performed within 2 days for fresh embryo transfer in the blastocyst stage (12). The main problem with blastomere biopsy was chromosome mosaicism. This is the phenomenon in which two or more kinds of genetically different cell populations are present within the same embryo. The mosaicism rate of blastomeres tends to vary from 18% to 57% (13,14). The biopsy of two cells from a blastomere may give increased accuracy but the biopsy of a single cell was associated with superior clinical outcome when compared with the two cell biopsy (15,16). Therefore, the biopsy of a single cell was recommended by ESHRE (17). Blastocyst biopsy is another approach where 5-10 cells of trophectoderm (TE) cells are biopsied with more reliable and accurate results leading to improved clinical outcomes (18)(19)(20)(21). Mosaicism is not major problem for blastocyst stage PGS because of the low incidence (20% to 33%) of mosaicism in the blastocyst stage (22)(23)(24). A previous study reported that the consistency between inner cell mass (ICM) and TE was 97% to 100% (19,25).

The disadvantage of blastocyst biopsy was the necessity for a short turnaround time in chromosome screening, thus leading to frozen embryo transfer. Even previous study reported that the clinical pregnancy rate of frozen blastocyst transfer was significantly higher than that of fresh blastomere transfer (26).

The method that was previously the gold standard for PGS was fluorescent in situ hybridization (FISH) utilizing a probe set of at least 8 chromosomes for aneuploidy screening as recommended by ESHRE (27,28). PGS with FISH analysis did not afford improved clinical outcome in blastomere and TE biopsy (20,29)(30)(31)(32)(33)(34)(35)(36)(37). Several factors could have caused the failure of FISH in improving the clinical outcome such as mosaicism, technical limitations and chromosome examination resulting in misdiagnosis (38).

The new technology of high throughput array comparative genomic hybridization (aCGH) is a technique that provides a comprehensive chromosome analysis of the embryo. When compared with FISH, aCGH provides a significantly higher interpretable result (96%) than does FISH (83%) (39). It displays the ability to detect 42% more chromosome errors and 13% more abnormal embryos compared with FISH using probes for 12 chromosomes (40). The reasons for the discordance in the results between FISH and aCGH are technical artifact and mosaicism (40). Mir et al. reported the false positive rate on blastomere aCGH to be 2.4 % and the false negative rate could not be detected (41). The error rate of aCGH ranged from 1.9% to 9% depending on the method of whole genome amplification used (40). The purpose of the present study was to investigate the prevalence of chromosome abnormalities of embryos of Asian populations using aCGH techniques.

II. Materials and Methods

This retrospective study was collected data from April 2014 to April 2015. Infertile couples undergoing IVF/ICSI were included into this study however those with known genetic disease were excluded. All cases were approved by the Ethics Committee of Ramathibodi Hospital, Faculty of Medicine, Mahidol University, Thailand. A total of 2,066 embryos from 281 patients were collected and tested using aCGH. All embryos biopsied were either blastomere or trophectoderm. Biopsied cells were load into a 0.2ml sterile microtube. The DNA was generated by whole genome amplification to microgram quantity DNA using half volume SurePlex DNA amplification kits according to the manufacturer's instructions (Illumina, San Diego, CA, USA) and the Sukprasert et al. study (42). Amplified DNA was verified by gel electrophoresis. DNA was labeled and hybridized according to the BlueGnome 24 sure protocol (available at www.cytochip.com). Chromosome copy number variation was analyzed by BlueFuse Multi software (Illumina, San Diego, CA, USA). The efficiency of the whole genome amplification was evaluated by gel electrophoresis. A successful amplification of 96.85 % (2001/2066 embryos) at least 90% for each marker is recommended by ESHRE (43). In addition, PGS with aCGH for screening chromosome aneuploidy in embryos showed the euploidy rate for all embryos was 42.23%. TE had a higher euploidy rate than blastomere especially in the young patient group (70.53%). In the blastomere group, the percentage of abnormal embryos was higher than the percentage of normal embryos for both the good and poor prognosis as shown in Figure 1. Complex chromosome abnormalities (more than one chromosome abnormality) were demonstrated to be the most common abnormalities of this study (66.44%) while monosomy and trisomy were minor (18.16% and 15.40%) as shown in Figure ??, similar to that reported in the Qi et al. study (44). The chromosomes least involved in aneuploidy were chromosomes Y, 8, 6, 12, and 3. We found that the types of aneuploidy in chromosomes were more gains than losses. The chromosomes most involved in aneuploidy were chromosomes 16, 19, 15, 20, and 22 (gain: chromosome 19, 15, 16, 22, and X; loss: chromosome 16, 9, 1, 2, and 20, respectively) as shown in Figure ??.

III. Results

A

The data was calculated using SPSS software to compare the results among the four groups. A value of $P < 0.05$ was considered statistically significant. IV.

Discussion

A meta-analysis of PGS demonstrated improving clinical outcomes because comprehensive chromosome screening with advanced technologies was used. The high throughput technology requires sufficient amount of DNA but the starting material from embryo biopsy has limited DNA quantity. Whole genome amplification technology solves this problem by amplifying DNA into microgram quantity yields, however the ability to amplify sufficient good quality DNA from a few cells depends highly on following the guideline protocol (43). Amplification failure causing the amplified DNA not sufficient for use in high throughput method may occur due to factors such as human error when loading cells into the microtubes or quality of cells being biopsied from the embryos.

The present study reports the primary outcome in chromosome abnormality of embryos and shows that the euploidy rate of blastocyst was high (62.99%), and correlates with other studies in which the euploidy rate ranged from 42% to 83% (22)(23)(24). We found that patients with AMA had high aneuploidy rates in both the blastomeres and trophectoderm because maternal age affects chromosome segregation during the development of oocyte, as shown in previous studies (45)(46)(47)(48).

Moreover, we found that the aneuploidy rate of blastomeres was 60.79%, in concordance with previous studies showing aneuploidy rates of 38% to 64% (39,40,49). In addition, the aneuploidy rate of blastocysts was 37.01% in concordance with ability of other techniques such as SNP microarray to detect aneuploidy rates of 15% to 52% (22)(23)(24). This study demonstrated a high incidence of chromosome aneuploidy in chromosomes 15, 16, 19, and 22, as did Dekel-Naftali et al. and Alfarawati et al. (50,51) but chromosome 20 was excluded.

The limitation of aCGH is that it detects copy number changes rather than polyploidy and haploid embryos. Gutierrez-Mateo reported 7.5% (6,898/92,018) of embryos were polyploid or haploid by FISH analysis. Most of these embryos had other abnormalities detectable by aCGH. Only 1.7% of embryos were polyploid or haploid undetectable by aCGH. Approximately 0.2% of embryos had homogeneous polyploidy or haploidy with good morphology demonstrated. Therefore, we estimated that the misdiagnosis rate due to non-detection of polyploidy is below 0.2 % (40).


This study is the first report of aneuploidy screening using aCGH in Thai patients. We investigated the primary outcome in a large sample size to study the incidence of chromosome abnormalities in embryos and found that the percentage of chromosomal abnormalities equal to the other studies. The limitation of this retrospective study is that we could not report the final outcome or livebirth rate.

6 V. Acknowledgements

There is no conflict of interest References Références Referencias The blastocysts had lower aneuploidy rates than blastomeres due to self-correction and mosaicism. The self-correction phenomenon is a process in the differentiating embryo for eliminating mosaicism by bringing about death and/or a decrease in abnormal cells (52). ??arbash



Figure 1: Figure 1 :



23

Figure 2: Figure 2 :Figure 3 :

1

total of 2,066 embryos from 281 patients were classified according to embryo stage and maternal age into four groups: group 1 were blastomeres from maternal age < 35yrs; group 2 were blastomeres from maternal age > 35yrs; group 3 were blastocysts from maternal age < 35yrs; and group 4 were blastocysts from maternal age > 35yrs (

Figure 3: Table 1 :

Scott

comprehensive chromosome screening results in improved ongoing pregnancy rates and decreased miscarriage rates. Hum. Reprod. 2012 Apr; 27 (4): 1217-22.

10. Keltz MD, Vega M, Sirota I, Lederman M, Moshier EL, Gonzales E, et al. Preimplantation genetic screening (PGS) with Comparative genomic hybridization (CGH) following day 3 single cell blastomere biopsy markedly improves IVF outcomes while lowering multiple pregnancies and

RTSingle embryo with

Figure 5:

[J. Assist. Reprod. Genet (2013)] , *J. Assist. Reprod. Genet* 2013 Oct. 30 (10) p. .

[Thornhill et al. (2009)] ‘A comparison of microarray methods to detect chromosomal aneuploidy in human preimplantation embryos’. A R Thornhill , H G Tempest , M Grigorova , N Affara , D K Griffin , A H Handyside . *Fertility and Sterility* 2009 Sep. 92 (3) p. S201.

[Meyer et al. (2009)] ‘A prospective randomized controlled trial of preimplantation genetic screening in the ”good prognosis’. L R Meyer , S Klipstein , W D Hazlett , T Nasta , P Mangan , V C Karande . *patient. Fertil. Steril* 2009 May. 91 (5) p. .

[Fragouli and Wells (2012)] ‘Aneuploidy Screening for Embryo Selection’. E Fragouli , D Wells . *Seminars in Reproductive Medicine* 2012 Aug. 30 (04) p. .

[Qi et al. (2014)] ‘Arrested human embryos are more likely to have abnormal chromosomes than developing embryos from women of advanced maternal age’. S-T Qi , L-F Liang , Y-X Xian , J-Q Liu , W Wang . *J Ovarian Res* 2014. 7 p. 65.

[Dekel-Naftali et al. (2013)] ‘Chromosomal integrity of human preimplantation embryos at different days post fertilization’. M Dekel-Naftali , A Aviram-Goldring , T Litmanovitch , J Shamash , H Yonath , A Hourvitz . *J. Assist. Reprod. Genet* 2013 Jun. 30 (5) p. .

[Voullaire et al. (2002)] ‘Chromosome abnormalities identified by comparative genomic hybridization in embryos from women with repeated implantation failure’. L Voullaire , L Wilton , J Mcbain , T Callaghan , R Williamson . *Mol. Hum. Reprod* 2002 Nov. 8 (11) p. .

[Márquez et al. (2000)] ‘Chromosome abnormalities in 1255 cleavage-stage human embryos’. C Márquez , M Sandalinas , M Bahçe , M Alikani , S Munné . *Reprod. Biomed. Online* 2000. 1 (1) p. .

[Staessen et al. (2004)] ‘Comparison of blastocyst transfer with or without preimplantation genetic diagnosis for aneuploidy screening in couples with advanced maternal age: a prospective randomized controlled trial’. C Staessen , P Platteau , E Van Assche , A Michiels , H Tournaye , M Camus . *Hum. Reprod* 2004 Dec. 19 (12) p. .

[Shen et al. (2014)] ‘Comparison of clinical outcomes between fresh embryo transfers and frozen-thawed embryo transfers’. C Shen , D Shu , X Zhao , Y Gao . *Iran J Reprod Med* 2014 Jun. 12 (6) p. .

[Johnson et al. (2010)] ‘Comprehensive analysis of karyotypic mosaicism between trophectoderm and inner cell mass’. D S Johnson , C Cinnioglu , R Ross , A Filby , G Gemelos , M Hill . *Mol. Hum. Reprod* 2010 Dec. 16 (12) p. .

[Fragouli et al. (2008)] ‘Comprehensive molecular cytogenetic analysis of the human blastocyst stage’. E Fragouli , M Lenzi , R Ross , M Katz-Jaffe , W B Schoolcraft , D Wells . *Hum. Reprod* 2008 Nov. 23 (11) p. .

[Fragouli et al. (2011)] ‘Cytogenetic analysis of human blastocysts with the use of FISH, CGH and aCGH: scientific data and technical evaluation’. E Fragouli , S Alfarawati , D D Daphnis , N-N Goodall , A Mania , T Griffiths . *Hum. Reprod* 2011 Feb. 26 (2) p. .

[Goossens et al. (2008)] ‘Diagnostic efficiency, embryonic development and clinical outcome after the biopsy of one or two blastomeres for preimplantation genetic diagnosis’. V Goossens , M De Rycke , De Vos , A Staessen , C Michiels , A Verpoest , W . *Human Reproduction* 2008 Mar 1. 23 (3) p. .

[Munné et al. (1995)] ‘Embryo morphology, developmental rates, and maternal age are correlated with chromosome abnormalities’. S Munné , M Alikani , G Tomkin , J Grifo , J Cohen . *Fertil. Steril* 1995 Aug. 64 (2) p. .

[Harton et al. (2011)] ‘ESHRE PGD consortium best practice guidelines for amplification-based PGD’. G L Harton , M De Rycke , F Fiorentino , C Moutou , S Sengupta , J Traeger-Synodinos . *Hum. Reprod* 2011 Jan. 26 (1) p. .

[Harton et al. (2011)] ‘ESHRE PGD consortium best practice guidelines for fluorescence in situ hybridization-based PGD’. G L Harton , J C Harper , E Coonen , T Pehlivan , K Vesela , L Wilton . *Hum. Reprod* 2011 Jan. 26 (1) p. .

[Moutou et al. (2009)] ‘ESHRE PGD Consortium data collection XII: cycles from’. C Moutou , V Goossens , E Coonen , M De Rycke , G Kokkali , P Renwick . *Human Reproduction* January to December 2009. October 2010. 2014 May 1. 29 (5) p. .

[Harton et al. (2011)] ‘ESHRE PGD Consortium/Embryology Special Interest Group–best practice guidelines for polar body and embryo biopsy for preimplantation genetic diagnosis/ screening (PGD/PGS)’. G L Harton , M C Magli , K Lundin , M Montag , J Lemmen , J C Harper . *Hum. Reprod* 2011 Jan. 26 (1) p. .

[Ethics Committee of the American Society for Reproductive Medicine. Shared-risk or refund programs in assisted reproduction]. ‘Ethics Committee of the American Society for Reproductive Medicine. Shared-risk or refund programs in assisted reproduction’. *Fertil. Steril* 2004 Sep. 82 (1) p. . (Suppl)

[Mir et al. (2013)] ‘False positive rate of an arrayCGH platform for single-cell preimplantation genetic screening and subsequent clinical application on day-3’. P Mir , L Rodrigo , A Mercader , P Buendía , E Mateu , M Milán-Sánchez . *Journal of Assisted Reproduction and Genetics* 2013 Jan. 30 (1) p. .

- [Capalbo et al. (2011)] ‘Fish reanalysis of inner cell mass and trophectoderm samples of previously array-CGH screened blastocysts reveals high accuracy of diagnosis and no sign of mosaicism or preferential allocation’. A Capalbo , G Wright , L Themaat , T Elliott , L Rienzi , Z P Nagy . *Fertility and Sterility* 2011 Sep. 96 (3) p. S22.
- [Baart (2004)] *Fluorescence in situ hybridization analysis of two blastomeres from day 3 frozen-thawed embryos followed by analysis of the remaining embryo on day 5. Human Reproduction*, E B Baart . 2004 Jan 29. 19 p.
- [De Vos et al. (2009)] ‘Impact of cleavagelstage embryo biopsy in view of PGD on human blastocyst implantation: a prospective cohort of single embryo transfers’. A De Vos , C Staessen , M De Rycke , W Verpoest , P Haentjens , P Devroey . *Hum. Reprod* 2009 Dec. 24 (12) p. .
- [Mastenbroek et al. (2007)] ‘In vitro fertilization with preimplantation genetic screening’. S Mastenbroek , M Twisk , J Van Echten-Arends , B Sikkema-Raddatz , J C Korevaar , H R Verhoeve . *N. Engl. J. Med* 2007 Jul 5. 357 (1) p. .
- [Munné et al. (2007)] ‘Maternal age, morphology, development and chromosome abnormalities in over 6000 cleavage-stage embryos’. S Munné , S Chen , P Colls , J Garrisi , X Zheng , N Cekleniak . *Reprod. Biomed. Online* 2007 May. 14 (5) p. .
- [Barbash-Hazan et al. (2009)] ‘Preimplantation aneuploid embryos undergo self-correction in correlation with their developmental potential’. S Barbash-Hazan , T Frumkin , M Malcov , Y Yaron , T Cohen , F Azem . *Fertility and Sterility* 2009 Sep. 92 (3) p. .
- [Schoolcraft et al. (2009)] ‘Preimplantation aneuploidy testing for infertile patients of advanced maternal age: a randomized prospective trial’. W B Schoolcraft , M G Katz-Jaffe , J Stevens , M Rawlins , S Munne . *Fertil. Steril* 2009 Jul. 92 (1) p. .
- [Harper and Sengupta (2012)] ‘Preimplantation genetic diagnosis: State of the ART 2011’. J C Harper , S B Sengupta . *Human Genetics* 2012 Feb. 131 (2) p. .
- [Staessen et al. (2008)] ‘Preimplantation genetic screening does not improve delivery rate in women under the age of 36 following single-embryo transfer’. C Staessen , W Verpoest , P Donoso , P Haentjens , J Van Der Elst , I Liebaers . *Hum. Reprod* 2008 Dec. 23 (12) p. .
- [Debrock et al. (2010)] ‘Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial’. S Debrock , C Melotte , C Spiessens , K Peeraer , E Vanneste , L Meeuwis . *Fertil. Steril* 2010 Feb. 93 (2) p. .
- [Hardarson et al. (2008)] ‘Preimplantation genetic screening in women of advanced maternal age caused a decrease in clinical pregnancy rate: a randomized controlled trial’. T Hardarson , C Hanson , K Lundin , T Hillensjö , L Nilsson , J Stevic . *Hum. Reprod* 2008 Dec. 23 (12) p. .
- [Mersereau et al. (2008)] ‘Preimplantation genetic screening to improve in vitro fertilization pregnancy rates: a prospective randomized controlled trial’. J E Mersereau , E Pergament , X Zhang , M P Milad . *Fertil. Steril* 2008 Oct. 90 (4) p. .
- [Blokceel et al. (2008)] ‘Prospectively randomized controlled trial of PGS in IVF/ICSI patients with poor implantation’. C Blokceel , V Schutyser , De Vos , A Verpoest , W , De Vos , M Staessen , C . *Reprod. Biomed. Online* 2008 Dec. 17 (6) p. .
- [Bazrgar et al. (2013)] ‘Self-correction of chromosomal abnormalities in human preimplantation embryos and embryonic stem cells’. M Bazrgar , H Gourabi , M R Valojerdi , P E Yazdi , H Baharvand . *Stem Cells Dev* 2013 Sep 1. 22 (17) p. .
- [Northrop et al. (2010)] ‘SNP microarray-based 24 chromosome aneuploidy screening demonstrates that cleavage-stage FISH poorly predicts aneuploidy in embryos that develop to morphologically normal blastocysts’. L E Northrop , N R Treff , B Levy , R T Scott . *Mol. Hum. Reprod* 2010 Aug. 16 (8) p. .
- [Treff et al. (2010)] ‘SNP microarray-based 24 chromosome aneuploidy screening is significantly more consistent than FISH’. N R Treff , B Levy , J Su , L E Northrop , X Tao , R T Scott . *Mol. Hum. Reprod* 2010 Aug. 16 (8) p. .
- [Hellani et al. (2008)] ‘Successful pregnancies after application of arraycomparative genomic hybridization in PGSaneuploidy screening’. A Hellani , K Abu-Amro , J Azouri , S El-Akoum . *Reprod. Biomed. Online* 2008 Dec. 17 (6) p. .
- [Sukprasert et al. (2013)] ‘The comparison of DNA quantity between full and half volume single cell whole genome amplification by linker-adaptor PCR technique’. M Sukprasert , S Rattanasiri , K Xu . *J Med Assoc Thai* 2013 Nov. 96 (11) p. .
- [Alfarawati et al. (2011)] ‘The relationship between blastocyst morphology, chromosomal abnormality, and embryo gender’. S Alfarawati , E Fragouli , P Colls , J Stevens , C Gutiérrez-Mateo , W B Schoolcraft . *Fertil. Steril* 2011 Feb. 95 (2) p. .

238 [Harper and Harton (2010)] ‘The use of arrays in preimplantation genetic diagnosis and screening’. J C Harper
239 , G Harton . *Fertility and Sterility* 2010 Sep. 94 (4) p. .

240 [Gutiérrez-Mateo et al. (2011)] ‘Validation of microarray comparative genomic hybridization for comprehensive
241 chromosome analysis of embryos’. C Gutiérrez-Mateo , P Colls , J Sánchez-García , T Escudero , R Prates ,
242 K Ketterson . *Fertil. Steril* 2011 Mar 1. 95 (3) p. .

243 [Jansen et al. (2008)] ‘What next for preimplantation genetic screening (PGS)? Experience with blastocyst
244 biopsy and testing for aneuploidy’. Rps Jansen , M C Bowman , De Boer , K A Leigh , D A Lieberman
245 , D B Mcarthur , SJ . *Hum. Reprod* 2008 Jul. 23 (7) p. .